Clinical usefulness of an ultra-high-sensitivity hepatitis B surface antigen assay to determine the cessation of treatment for HBV reactivation

The iTACT-HBsAg assay was useful to determine the cessation of NA treatment to prevent against HBV reactivation.

Authors

Yasuhito Tanaka (ORCID: https://orcid.org/0000-0003-1435-462X)
Shigeru Kusumoto (ORCID: https://orcid.org/0000-0001-6546-1279)
Shinya Hagiwara (ORCID: https://orcid.org/0009-0000-7730-2531)
Katsumi Aoyagi (ORCID: https://orcid.org/0000-0003-3818-7985)
Atsushi Kaneko (ORCID: https://orcid.org/0000-0003-4392-912X)
Hiromi Kataoka (ORCID: https://orcid.org/0000-0001-9491-0723)
Ritsuzo Kozuka (ORCID: https://orcid.org/0000-0002-0763-6760)
Kei Fujiwara (ORCID: https://orcid.org/0000-0001-7308-774X)
Akihiro Tamori (ORCID: https://orcid.org/0000-0001-9119-4864)
Shuko Murakami (ORCID: https://orcid.org/0000-0002-1720-2712)
Masaru Enomoto (ORCID: https://orcid.org/0000-0002-4028-4381)
Takanori Suzuki (ORCID: https://orcid.org/0000-0002-8940-2393)
Haruka Sagi
Kentaro Matsuura (ORCID: https://orcid.org/0000-0001-5262-055X)
Takako Inoue
Hayato Kawamra